Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 3,274
Change Today +113.00 / 3.57%
Volume 2.5K
As of 10:24 AM 05/25/15 All times are local (Market data is delayed by at least 15 minutes).

intec pharma ltd (INTP) Snapshot

Open
$3,161
Previous Close
$3,161
Day High
$3,275
Day Low
$3,161
52 Week High
07/30/14 - $4,520
52 Week Low
12/29/14 - $1,750
Market Cap
183.6M
Average Volume 10 Days
6.1K
EPS TTM
$-4.10
Shares Outstanding
5.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTEC PHARMA LTD (INTP)

Related News

No related news articles were found.

intec pharma ltd (INTP) Related Businessweek News

No Related Businessweek News Found

intec pharma ltd (INTP) Details

Intec Pharma Ltd., a drug development company, develops improved formulations of drugs using gastric retention technology. Its product portfolio includes Accordion Pill Carbidopa/Levodopa, a Phase II gastric-retentive dosage form for the treatment of Parkinson’s disease; and Accordion Pill – Zaleplon, a Phase II drug for treatment of insomnia. The company is based in Jerusalem, Israel.

intec pharma ltd (INTP) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: --
Co-Founder and Chairman
Total Annual Compensation: 513.1K
Vice President of R&D & Operations
Total Annual Compensation: 474.6K
Compensation as of Fiscal Year 2013.

intec pharma ltd (INTP) Key Developments

Intec Pharma Forms Drug Development Partnership with Unnamed Pharma Company

Intec Pharma has announced the signing of a development and licensing agreement with an unnamed international pharmaceutical company. The agreement involves Intec undertaking research examining the potential to incorporate its Accordion Pill technology with a novel drug marketed by the international pharmaceutical company. Research will be funded by the pharmaceutical company, which also retains the option to commercialise any related product. The financial terms of the deal include USD 250,000 in upfront payments, with USD 670,000 subject to research milestones. Further payments of USD 8 million and USD 39 million would be made should the option of later-stage clinical development be exercised and relevant development milestones related to this be reached. Should a product reach market, Intec would receive low single-digit royalties up to USD 25 million annually or USD 100 million over the product's life cycle. A copy of Intec's press release detailing the deal can be accessed here.

Intec Pharma Ltd., Annual General Meeting, Mar 18, 2015

Intec Pharma Ltd., Annual General Meeting, Mar 18, 2015., at 11:00 Israel Standard Time.

US Food and Drug Administration Gives Phase III Nod for Intec Pharma Ltd.'s Parkinson Treatment

Intec Pharma Ltd. announced that it had received US Food and Drug Administration (FDA) approval for carrying out a Phase III trial of its Accordion Pill Levodopa for the treatment of Parkinson's Disease. The Accordion Pill is a gastro-retentive drug delivery system.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INTP:IT 3,274.00 +113.00

INTP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for INTP.
View Industry Companies
 

Industry Analysis

INTP

Industry Average

Valuation INTP Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTEC PHARMA LTD, please visit www.intecpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.